首页 > 最新文献

Annals of Internal Medicine最新文献

英文 中文
Information Disclosure, Medical Device Regulation, and Device Safety: The Case of Cook Celect IVC Filters. 信息披露、医疗器械监管和设备安全:Cook Celect IVC 过滤器案例。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-00089
Kushal T Kadakia, Behnood Bikdeli, Aakriti Gupta, Sanket S Dhruva, Joseph S Ross, Harlan M Krumholz

Although medical devices are widely used in clinical practice, clinicians and the public have limited access to information on how devices are tested, regulated, and used, posing challenges to patient safety. This article uses Cook Medical's Celect inferior vena cava (IVC) filter, a medical device used for prevention of pulmonary embolism, as a case study of the transparency gap in medical device regulation. Recently unsealed court documents from litigation related to Celect reveal that the device's clinical study protocol did not follow U.S. Food and Drug Administration (FDA) guidance for IVC filter testing and that study outcome definitions for IVC perforation had lower sensitivity for detecting adverse events than those recommended by professional societies. Furthermore, a comparison of court documents and the public record indicates that adverse events and patient deaths were misreported to FDA reviewers and were inaccurately reported in the published literature and on the device label, providing patients and clinicians with inaccurate information about the device's safety. The Celect IVC filter case demonstrates the need for regulatory reforms to ensure that critical safety data are accessible to the FDA, clinicians, and patients to inform decision making.

尽管医疗器械被广泛应用于临床实践,但临床医生和公众获取有关医疗器械如何测试、监管和使用的信息却十分有限,这给患者安全带来了挑战。本文以库克医疗公司的Celect下腔静脉(IVC)过滤器(一种用于预防肺栓塞的医疗器械)为案例,分析医疗器械监管的透明度差距。最近解封的与 Celect 相关诉讼的法庭文件显示,该设备的临床研究方案没有遵循美国食品药品管理局(FDA)的 IVC 过滤器测试指南,而且 IVC 穿孔的研究结果定义对不良事件的检测灵敏度低于专业协会推荐的定义。此外,对法庭文件和公开记录的比较表明,不良事件和患者死亡情况被错误地报告给了 FDA 评审人员,并且在发表的文献和器械标签上也有不准确的报告,从而为患者和临床医生提供了不准确的器械安全性信息。Celect IVC 过滤器事件表明,有必要进行监管改革,以确保 FDA、临床医生和患者都能获得重要的安全数据,从而为决策提供依据。
{"title":"Information Disclosure, Medical Device Regulation, and Device Safety: The Case of Cook Celect IVC Filters.","authors":"Kushal T Kadakia, Behnood Bikdeli, Aakriti Gupta, Sanket S Dhruva, Joseph S Ross, Harlan M Krumholz","doi":"10.7326/ANNALS-24-00089","DOIUrl":"10.7326/ANNALS-24-00089","url":null,"abstract":"<p><p>Although medical devices are widely used in clinical practice, clinicians and the public have limited access to information on how devices are tested, regulated, and used, posing challenges to patient safety. This article uses Cook Medical's Celect inferior vena cava (IVC) filter, a medical device used for prevention of pulmonary embolism, as a case study of the transparency gap in medical device regulation. Recently unsealed court documents from litigation related to Celect reveal that the device's clinical study protocol did not follow U.S. Food and Drug Administration (FDA) guidance for IVC filter testing and that study outcome definitions for IVC perforation had lower sensitivity for detecting adverse events than those recommended by professional societies. Furthermore, a comparison of court documents and the public record indicates that adverse events and patient deaths were misreported to FDA reviewers and were inaccurately reported in the published literature and on the device label, providing patients and clinicians with inaccurate information about the device's safety. The Celect IVC filter case demonstrates the need for regulatory reforms to ensure that critical safety data are accessible to the FDA, clinicians, and patients to inform decision making.</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation. 地诺单抗对慢性肾脏病各期急诊治疗低钙血症风险的影响:目标试验模拟。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/M24-0013
Steven T Bird, Kate Gelperin, Elizabeth R Smith, Tae Hyun Jung, Hai Lyu, Aliza Thompson, Olivia Easley, Kushal B Naik, Yueqin Zhao, Rekha Kambhampati, Michael Wernecke, Ali Niak, Marina Zemskova, Yoganand Chillarige, Jeffrey A Kelman, David J Graham

Background: There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD).

Objective: To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD-mineral and bone disorder (CKD-MBD).

Design: Target trial emulation.

Setting: Medicare fee-for-service data with prescription drug coverage, 2012 to 2020.

Participants: Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis.

Measurements: Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated.

Results: A total of 361 453 patients treated with denosumab, 829 044 treated with oral bisphosphonates, and 160 413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (P < 0.001), with greatest risk among dialysis-dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non-dialysis-dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD + DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD-MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates.

Limitation: Generalizability to men and non-Medicare populations.

Conclusion: Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD-MBD.

Primary funding source: U.S. Food and Drug Administration.

背景:有关晚期慢性肾脏病(CKD)患者骨质疏松症治疗的数据很少:有关晚期慢性肾脏病(CKD)患者骨质疏松症治疗的数据很少:根据慢性肾脏病的分期以及是否存在慢性肾脏病-矿物质和骨质紊乱(CKD-MBD),评估使用地诺单抗紧急治疗低钙血症的风险:设计:目标试验模拟:2012年至2020年有处方药保险的医疗保险付费服务数据:年龄在 65 岁或以上、因骨质疏松症开始使用地诺单抗、口服双膦酸盐或静脉注射双膦酸盐的女性患者:测量方法:对最初 12 个治疗周内因低钙血症入院和急诊(即急诊)的情况进行评估。计算治疗加权累积发生率的逆概率和加权风险差异(RDs):结果:共确定了361 453名接受地诺单抗治疗的患者、829 044名接受口服双膦酸盐治疗的患者和160 413名接受静脉注射双膦酸盐治疗的患者。与口服双膦酸盐相比,使用地诺单抗紧急治疗低钙血症的风险随着慢性肾脏病分期的恶化而增加(P 限制:可推广至男性和非医保人群:主要资金来源:美国食品和药物管理局:主要资金来源:美国食品和药物管理局。
{"title":"The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial Emulation.","authors":"Steven T Bird, Kate Gelperin, Elizabeth R Smith, Tae Hyun Jung, Hai Lyu, Aliza Thompson, Olivia Easley, Kushal B Naik, Yueqin Zhao, Rekha Kambhampati, Michael Wernecke, Ali Niak, Marina Zemskova, Yoganand Chillarige, Jeffrey A Kelman, David J Graham","doi":"10.7326/M24-0013","DOIUrl":"10.7326/M24-0013","url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD).</p><p><strong>Objective: </strong>To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD-mineral and bone disorder (CKD-MBD).</p><p><strong>Design: </strong>Target trial emulation.</p><p><strong>Setting: </strong>Medicare fee-for-service data with prescription drug coverage, 2012 to 2020.</p><p><strong>Participants: </strong>Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis.</p><p><strong>Measurements: </strong>Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated.</p><p><strong>Results: </strong>A total of 361 453 patients treated with denosumab, 829 044 treated with oral bisphosphonates, and 160 413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (<i>P</i> < 0.001), with greatest risk among dialysis-dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non-dialysis-dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD + DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD-MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates.</p><p><strong>Limitation: </strong>Generalizability to men and non-Medicare populations.</p><p><strong>Conclusion: </strong>Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD-MBD.</p><p><strong>Primary funding source: </strong>U.S. Food and Drug Administration.</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increasing Incidence and Stable Mortality of Pancreatic Cancer in Young Americans. 美国年轻人胰腺癌发病率上升,死亡率稳定。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-00635
Vishal R Patel, Adewole S Adamson, Jason B Liu, H Gilbert Welch
{"title":"Increasing Incidence and Stable Mortality of Pancreatic Cancer in Young Americans.","authors":"Vishal R Patel, Adewole S Adamson, Jason B Liu, H Gilbert Welch","doi":"10.7326/ANNALS-24-00635","DOIUrl":"10.7326/ANNALS-24-00635","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peer Review: Insights Gleaned From Observing the Editorial Process at Annals of Internal Medicine. 同行评审:从观察《内科学年鉴》编辑过程中获得的启示》。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-01737
Yuri Matusov, Taylor Brooks, Desiree Burroughs-Ray, Maniraj Neupane
{"title":"Peer Review: Insights Gleaned From Observing the Editorial Process at <i>Annals of Internal Medicine</i>.","authors":"Yuri Matusov, Taylor Brooks, Desiree Burroughs-Ray, Maniraj Neupane","doi":"10.7326/ANNALS-24-01737","DOIUrl":"10.7326/ANNALS-24-01737","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia. 更正:社区获得性肺炎的诊断不一致、不确定性和治疗模糊性。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-02850
{"title":"Correction: Diagnostic Discordance, Uncertainty, and Treatment Ambiguity in Community-Acquired Pneumonia.","authors":"","doi":"10.7326/ANNALS-24-02850","DOIUrl":"10.7326/ANNALS-24-02850","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Illuminating the Value of Palliative Care in Cancer: A Path to Incentivizing High-Value Cancer Care. 阐明癌症姑息治疗的价值:激励高价值癌症护理的途径。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-00702
Xin Hu, Boshen Jiao, Xiaoyu Pan, Ryan Nipp, Changchuan Jiang
{"title":"Illuminating the Value of Palliative Care in Cancer: A Path to Incentivizing High-Value Cancer Care.","authors":"Xin Hu, Boshen Jiao, Xiaoyu Pan, Ryan Nipp, Changchuan Jiang","doi":"10.7326/ANNALS-24-00702","DOIUrl":"10.7326/ANNALS-24-00702","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oropouche Virus: A Rising Threat in the Western Hemisphere. 奥罗普切病毒:西半球日益严重的威胁。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-19 DOI: 10.7326/ANNALS-24-03049
Kevin O'Laughlin, Ralph Huits, Michael Libman, Phyllis Kozarsky, Davidson H Hamer
{"title":"Oropouche Virus: A Rising Threat in the Western Hemisphere.","authors":"Kevin O'Laughlin, Ralph Huits, Michael Libman, Phyllis Kozarsky, Davidson H Hamer","doi":"10.7326/ANNALS-24-03049","DOIUrl":"10.7326/ANNALS-24-03049","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From Risk to Recovery: Looking Ahead to the Next 50 Years of Preoperative Cardiovascular Assessment. 从风险到康复:展望未来 50 年的术前心血管评估。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-12 DOI: 10.7326/ANNALS-24-02405
Lauren E Gibson, Jeanine P Wiener-Kronish, Lee A Fleisher
{"title":"From Risk to Recovery: Looking Ahead to the Next 50 Years of Preoperative Cardiovascular Assessment.","authors":"Lauren E Gibson, Jeanine P Wiener-Kronish, Lee A Fleisher","doi":"10.7326/ANNALS-24-02405","DOIUrl":"https://doi.org/10.7326/ANNALS-24-02405","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body Surface Area in Obesity: Clinical Challenges and Call for Improvements. 肥胖症的体表面积:临床挑战与改进呼吁。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-12 DOI: 10.7326/M24-0574
Haoyi Zheng, Huichun Zhan
{"title":"Body Surface Area in Obesity: Clinical Challenges and Call for Improvements.","authors":"Haoyi Zheng, Huichun Zhan","doi":"10.7326/M24-0574","DOIUrl":"https://doi.org/10.7326/M24-0574","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142611947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Misuse of Race in the Interpretation of HbA1c. 在解释 HbA1c 时滥用种族。
IF 19.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-12 DOI: 10.7326/ANNALS-24-01661
Elizabeth Selvin
{"title":"Misuse of Race in the Interpretation of HbA<sub>1c</sub>.","authors":"Elizabeth Selvin","doi":"10.7326/ANNALS-24-01661","DOIUrl":"https://doi.org/10.7326/ANNALS-24-01661","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of Internal Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1